Skip to main
NVAX
NVAX logo

Novavax (NVAX) Stock Forecast & Price Target

Novavax (NVAX) Analyst Ratings

Based on 7 analyst ratings
Hold
Strong Buy 29%
Buy 14%
Hold 14%
Sell 29%
Strong Sell 14%

Bulls say

Novavax Inc. has revised its financial outlook for fiscal year 2025, slightly increasing its revenue framework from $1-$1.05 billion to $1.04-$1.06 billion, indicating a positive trend in projected financial performance. The company has recorded $225 million in milestones year-to-date, with an expectation of an additional $50 million contribution in the fourth quarter for U.S. and EU marketing authorization transfers, showcasing strong operational progress. Furthermore, Novavax's working capital has improved to $544.7 million, reflecting better financial health that facilitates continued investment in its core vaccine development initiatives.

Bears say

Novavax Inc has reported a significant reduction in cash equivalents, declining from $938.2 million to $778.2 million, indicating a concerning operational cash burn that may jeopardize ongoing projects. The company also experienced a 17% year-over-year revenue decline, largely due to a transition in commercial responsibility which resulted in a substantial decrease in revenue from $71 million in the third quarter of 2024, reflecting a 55% year-over-year drop. Furthermore, if their vaccine candidates, such as NanoFlu, fail to demonstrate a competitive edge over existing options, the company may struggle to achieve revenue generation, worsening its financial outlook.

Novavax (NVAX) has been analyzed by 7 analysts, with a consensus rating of Hold. 29% of analysts recommend a Strong Buy, 14% recommend Buy, 14% suggest Holding, 29% advise Selling, and 14% predict a Strong Sell.

This aggregate rating is based on analysts' research of Novavax and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Novavax (NVAX) Forecast

Analysts have given Novavax (NVAX) a Hold based on their latest research and market trends.

According to 7 analysts, Novavax (NVAX) has a Hold consensus rating as of Nov 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Novavax (NVAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.